Halozyme Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $325,719 | $264,861 | $298,008 | $290,084 |
Gross Profit | 279,360 | 216,458 | 255,953 | 240,658 |
EBITDA | 229,834 | 168,802 | 203,169 | 190,033 |
EBIT | 209,332 | 148,353 | 182,754 | 169,671 |
Net Income | 165,160 | 118,095 | 137,012 | 137,011 |
Net Change In Cash | 325,719 | 264,861 | 298,008 | 290,084 |
Free Cash Flow | 98,148 | 153,271 | 175,415 | 113,859 |
Cash | 61,861 | 176,328 | 115,850 | 154,318 |
Basic Shares | 124,158 | 126,644 | 129,424 | 130,134 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $1,015,324 | $829,253 | $660,116 | $443,310 |
Gross Profit | 855,907 | 636,892 | 520,812 | 361,897 |
EBITDA | 656,539 | 451,947 | 315,506 | 278,899 |
EBIT | 575,227 | 367,091 | 265,865 | 275,902 |
Net Income | 444,091 | 281,594 | 202,129 | 402,710 |
Net Change In Cash | 1,015,324 | 829,253 | 660,116 | 443,310 |
Cost of Revenue | 115,476 | -28,984 | ||
Free Cash Flow | 468,368 | 373,277 | 235,300 | 297,983 |
Cash | 115,850 | 118,370 | 234,195 | 118,719 |
Basic Shares | 129,424 | 134,197 | 140,608 | 146,796 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | $1.54 |
2025-03-31 | $1.11 |
2024-12-31 | $1.26 |
2024-09-30 | $1.27 |
